Search results for: Genetic
Filter search results
Franz Pichler
10 April 2026
Franz Pichler, PhD, is Principal and Founder of Confluence Health Consulting, a firm that specializes in pharmaceutical external affairs. Franz received his PhD in Genetics from the University of Auckland…
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
1 June 2022
…known monogenic (single gene) cause. In contrast to traditional small molecule medicines, gene therapies have the potential to correct underlying genetic defects, offering the potential for transformational health gains rather…
Amanda Cole
30 May 2014
…healthcare technology development and adoption. Amanda has a special interest in rare diseases and serves on several advisory groups, including Genetic Alliance UK’s Patient Empowerment Group, England’s Rare Disease Action…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…was the moderator for this session. She is a co-author of the report as well as expert in the field of economic evaluation of genetic diagnostics and precision oncology. She…
OHE Lunchtime Seminar: Early Experience with HTA of Gene Therapies in the US: Pricing and Paying for Cures
21 October 2018, 11:00pm
…haemophilia, sickle cell disease, and numerous other genetically-based conditions. Individually, each treatment will be extremely expensive, and in the aggregate their costs are projected to have a substantial impact on…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…view other videos from the Translation Genomics Event presented by the NHS’s National Genetics Education and Development Centre click here. Challenges in Valuing Genomic Medicines from Office of Health Economics…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…offer improvement for patients. Taking the second and third factors into account, ICER’s panel majority found Luxturna, for genetic retinal disease causing blindness, to represent “intermediate long term value for…
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…(identifying genetic risks), secondary (early detection) and tertiary (personalised treatment) prevention, which will also require coordination across laboratories, specialist care and community services. There is additional complexity added to this…
Sukanya Subramaniyan
3 October 2024
…at the University of Cambridge. Her master’s thesis investigated the association between rare germline genetic variation and the risk of epithelial ovarian cancer. Sukanya’s current research interests include modelling methods…